Is IMUX or OCS more profitable?

Immunic has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Oculis -6,777.18% -42.61% -35.23%

Does the media favor IMUX or OCS?

In the previous week, Immunic had 6 more articles in the media than Oculis. MarketBeat recorded 10 mentions for Immunic and 4 mentions for Oculis. Oculis' average media sentiment score of 0.80 beat Immunic's score of 0.48 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to AQST or IMUX?

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Immunic. MarketBeat recorded 12 mentions for Aquestive Therapeutics and 10 mentions for Immunic. Aquestive Therapeutics' average media sentiment score of 0.71 beat Immunic's score of 0.48 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CRMD or IMUX?

CorMedix has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 1.96 $163.05M $2.14 3.65 Immunic N/A N/A -$97.17M -$4.38 N/A

Is CRMD or IMUX more profitable?

CorMedix has a net margin of 40.49% compared to Immunic's net margin of 0.00%. CorMedix's return on equity of 40.52% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets CorMedix 40.49% 40.52% 20.61% Immunic N/A -157.89% -107.88%

Does the media refer more to CRMD or IMUX?

In the previous week, Immunic had 4 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Immunic and 6 mentions for CorMedix. CorMedix's average media sentiment score of 0.97 beat Immunic's score of 0.48 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, IMUX or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is IMUX or DRUG more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Bright Minds Biosciences N/A -12.46% -12.30%

Is CTNM or IMUX more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -24.73% -23.51% Immunic N/A -157.89% -107.88%

Does the media prefer CTNM or IMUX?

In the previous week, Immunic had 4 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Immunic and 6 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.00 beat Immunic's score of 0.48 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immunic (IMUX) Competitors

$11.42 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.38 -0.04 (-0.39%)

As of 09/11/2026 07:30 PM Eastern

Compare

IMUX vs. OCS, AQST, CRMD, DRUG, and CTNM

Should you buy Immunic stock or one of its competitors? Immunic's main competitors and comparable companies include Oculis (OCS), Aquestive Therapeutics (AQST), CorMedix (CRMD), Bright Minds Biosciences (DRUG), and Contineum Therapeutics (CTNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Immunic compare to Oculis?

Immunic (NASDAQ:IMUX) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Immunic has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Oculis	$1.45M	422.25	-$119.44M	-$1.74	N/A

Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Oculis has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Immunic currently has a consensus price target of $47.25, suggesting a potential upside of 313.75%. Oculis has a consensus price target of $38.00, suggesting a potential upside of 259.85%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Immunic has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Oculis' return on equity of -42.61% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Oculis	-6,777.18%	-42.61%	-35.23%

51.8% of Immunic shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Immunic had 6 more articles in the media than Oculis. MarketBeat recorded 10 mentions for Immunic and 4 mentions for Oculis. Oculis' average media sentiment score of 0.80 beat Immunic's score of 0.48 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Immunic beats Oculis on 10 of the 16 factors compared between the two stocks.

How does Immunic compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aquestive Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Immunic has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Aquestive Therapeutics has higher revenue and earnings than Immunic. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	13.47	-$83.78M	-$0.65	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Aquestive Therapeutics presently has a consensus target price of $9.17, suggesting a potential upside of 91.77%. Immunic has a consensus target price of $47.25, suggesting a potential upside of 313.75%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Immunic has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Immunic	N/A	-157.89%	-107.88%

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Immunic. MarketBeat recorded 12 mentions for Aquestive Therapeutics and 10 mentions for Immunic. Aquestive Therapeutics' average media sentiment score of 0.71 beat Immunic's score of 0.48 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aquestive Therapeutics beats Immunic on 9 of the 16 factors compared between the two stocks.

How does Immunic compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

CorMedix has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.96	$163.05M	$2.14	3.65
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

CorMedix has a net margin of 40.49% compared to Immunic's net margin of 0.00%. CorMedix's return on equity of 40.52% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Immunic	N/A	-157.89%	-107.88%

34.2% of CorMedix shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Immunic had 4 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Immunic and 6 mentions for CorMedix. CorMedix's average media sentiment score of 0.97 beat Immunic's score of 0.48 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 91.82%. Immunic has a consensus price target of $47.25, suggesting a potential upside of 313.75%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

CorMedix has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Summary

CorMedix beats Immunic on 9 of the 16 factors compared between the two stocks.

How does Immunic compare to Bright Minds Biosciences?

Immunic (NASDAQ:IMUX) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Immunic currently has a consensus price target of $47.25, indicating a potential upside of 313.75%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 127.66%. Given Immunic's higher possible upside, equities analysts clearly believe Immunic is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bright Minds Biosciences' return on equity of -12.46% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

In the previous week, Immunic had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 10 mentions for Immunic and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat Immunic's score of 0.48 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunic	Neutral
Bright Minds Biosciences	Very Positive

51.8% of Immunic shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immunic has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, meaning that its share price is 636% less volatile than the broader market.

Summary

Immunic and Bright Minds Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Immunic compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Contineum Therapeutics' return on equity of -24.73% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Immunic	N/A	-157.89%	-107.88%

Contineum Therapeutics presently has a consensus price target of $20.25, indicating a potential upside of 36.64%. Immunic has a consensus price target of $47.25, indicating a potential upside of 313.75%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

51.8% of Immunic shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Immunic had 4 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Immunic and 6 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.00 beat Immunic's score of 0.48 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Contineum Therapeutics has higher revenue and earnings than Immunic. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	11.15	-$59.98M	-$1.73	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Contineum Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Summary

Immunic beats Contineum Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$155.77M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-2.61	799.75	274.94	25.33
Price / Sales	N/A	756.96	633.80	90.72
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	-20.76	10.39	10.33	6.21
Net Income	-$97.17M	$2.85B	$3.50B	$358.54M
7 Day Performance	-12.89%	-3.62%	-3.32%	-2.35%
1 Month Performance	-28.89%	0.47%	-0.87%	-3.37%
1 Year Performance	43.77%	3.56%	23.50%	8.81%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	3.12 of 5 stars	$11.42 flat	$47.25 +313.7%	+43.8%	$155.77M	N/A	N/A	70	News Coverage Analyst Forecast
OCS Oculis	2.1298 of 5 stars	$12.17 flat	$38.00 +212.2%	-39.3%	$705.67M	$1.45M	N/A	2	News Coverage
AQST Aquestive Therapeutics	2.5159 of 5 stars	$5.34 flat	$8.80 +64.8%	-5.3%	$670.23M	$44.54M	N/A	160	Analyst Upgrade Gap Up
CRMD CorMedix	2.9647 of 5 stars	$8.43 flat	$15.00 +77.9%	-39.6%	$657.07M	$311.71M	4.44	30	Gap Up
DRUG Bright Minds Biosciences	3.0484 of 5 stars	$65.16 flat	$143.83 +120.7%	+29.6%	$634.15M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. OCS, AQST, CRMD, DRUG, and CTNM

How does Immunic compare to Oculis?

Summary

How does Immunic compare to Aquestive Therapeutics?

Summary

How does Immunic compare to CorMedix?

Summary

How does Immunic compare to Bright Minds Biosciences?

Summary

How does Immunic compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. OCS, AQST, CRMD, DRUG, and CTNM

How does Immunic compare to Oculis?

Which has higher earnings & valuation, IMUX or OCS?

Which has more risk and volatility, IMUX or OCS?

Do analysts recommend IMUX or OCS?

Is IMUX or OCS more profitable?

Do institutionals & insiders hold more shares of IMUX or OCS?

Does the media favor IMUX or OCS?

Summary

How does Immunic compare to Aquestive Therapeutics?

Do institutionals and insiders have more ownership in AQST or IMUX?

Which has more risk and volatility, AQST or IMUX?

Which has stronger earnings and valuation, AQST or IMUX?

Do analysts prefer AQST or IMUX?

Is AQST or IMUX more profitable?

Does the media refer more to AQST or IMUX?

Summary

How does Immunic compare to CorMedix?

Which has higher valuation and earnings, CRMD or IMUX?

Is CRMD or IMUX more profitable?

Do institutionals & insiders have more ownership in CRMD or IMUX?

Does the media refer more to CRMD or IMUX?

Do analysts rate CRMD or IMUX?

Which has more volatility and risk, CRMD or IMUX?

Summary

How does Immunic compare to Bright Minds Biosciences?

Which has stronger valuation & earnings, IMUX or DRUG?

Do analysts recommend IMUX or DRUG?

Is IMUX or DRUG more profitable?

Does the media prefer IMUX or DRUG?

Do institutionals and insiders believe in IMUX or DRUG?

Which has more volatility and risk, IMUX or DRUG?

Summary

How does Immunic compare to Contineum Therapeutics?

Is CTNM or IMUX more profitable?

Do analysts rate CTNM or IMUX?

Do insiders & institutionals believe in CTNM or IMUX?

Does the media prefer CTNM or IMUX?

Which has higher valuation & earnings, CTNM or IMUX?

Which has more risk & volatility, CTNM or IMUX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools